However, Robert Popescu, the chief executive of A&D Pharma group, the leading company in the domestic drug industry, says he is thinking of revising this year’s budget from a two-digit growth rate to a single-digit one “in an upbeat scenario”, as the industry’s trend lags behind initial expectations.

The revision may be done even earlier than normally.

“The targets must be in line with market expectations. (Market researchers) Cegedim said at the start of the year that the market would rise by over 10%. After the first quarter, it said the market would grow by 3%-4%. It’s a huge difference. In value the market expanded, but in terms of volume it shrank (in the first quarter),” Popescu said.

Thus, he continued, it is “almost impossible” to make a plan for a 15% or 20% increase and keep this target on a market you expecte to rise by 12%-14%.

Legislative changes also weighed heavily in A&D Pharma’s decision to revise its budget.

A&D Pharma group operates Mediplus, Sensiblu, a marketing & sales unit, and a recent project involving Anima clinics.

Mediplus last year reached turnover of RON2.33 billion (EUR533 million), up almost 19% from 2009. At the end of 2010, the unit had 1,046 employees, compared with 1,174 in 2009.

At the same time, Sensiblu posted sales of RON989 million (EUR234.9 million), 21% higher than in 2009. The pharmacy network, which this year took over another chain, Farmaplanet, had 1,920 employees in 2010, from 1,799 in 2009. At present, the network has 250 pharmacies.

In 2009, A&D Pharma registered consolidated turnover worth EUR514.3 million. There is no information available on 2010 consolidated turnover, but Robert Popescu says that while in 2009 it started with 5, in 2010 “6 or 7 seems more logical”, considering the acquired entities were integrated.

Starting March, A&D Pharma reverted to the private company status, which it had before 2006. After delisting, Popescu says decisions are easier to make, but he will not change the internal rules of the group.